19 June 2013
Keywords: repligen, plans, pivotal, trials, autism, drug, said
Article | 05 November 2001
Repligen has said it intends to conduct two Phase III clinical trials ofits candidate drug for moderate-to-severe pediatric autism, secretin,
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
25 February 2002
21 June 2001
18 June 2013
© 2013 thepharmaletter.com